TLR1 and neoplasm: In tumor models of lung cancer, leukemia, and melanoma, TLR1/2 antagonists suppress the inhibitory function of Foxp3+ Tregs, enhance the cytotoxicity of tumor-specific CTLs, and lead to the depletion of tumor-infiltrating Treg cells (120, 121).